the company

Meletios Therapeutics’ aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections.

This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers.

One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II.

Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses.

Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.

STRENGTHS OF MELETIOS

Visual Capitalist

THE CONTEXT

As far back as we can remember, there has always been a real concern for human communities about epidemics which have been incredibly devastating in the past. And we are nowadays seeing a speeding up of the phenomenon. We are increasingly interconnected and pushing the boundaries of our environment further and further, yielding unknown viruses to come out into the open.

There is thus a real need to anticipate the emergence of new viruses that could lead to globalized epidemics such as COVID-19.

WHY IS THERE A CRITICAL NEED FOR ANTIVIRALS?

To tackle future emerging viruses, every effort must be made to channel epidemics. Vaccines and treatments are two complementary therapeutic strategies.

Vaccines are an essential preventive tool but have the disadvantages of targeting a virus that must be already (well) known and of being uncertain about possible variants. They can be also time-consuming to implement.

An alternative is therefore needed for patients who are already ill in order to treat their symptoms and to resolve the infection from the start of the epidemic. There is a significant need for broad-spectrum therapies that have a low risk of inducing treatment resistance and can be administered throughout the course of the disease, not just in the first few days after infection.

A need for broad-spectrum antivirals to rapidly save patientslives regardless the virus strain causing the pandemic
DISEASES

We are facing an increasing number of pandemic situations

New viruses are to emerge with a lack of overlap between viruses

VACCINES

= PREVENTION

Vaccines are mostly efficient against one strain only

Implementation in the population takes long

Viral genome are small and evolve rapidly

It is sometimes impossible
to design a vaccine for a virus

ANTIVIRAL

= CURE

The current antiviral armamentarium is not sufficient to face current and future epidemics

Broad spectrum treatment could be used as soon as a viral pandemic is identified

Antivirals will be efficacious against a large panel of viruses

MELETIOS TEAM

CATHERINE MARTRE
CATHERINE MARTRE CEO
25 years of biotech & pharma experience, strategic and operational positions, Engineer graduated from Ecole Centrale.
MARC SALOMÉ
MARC SALOMÉ Senior Scientist
Co-founder of Meletios, engineer from ETH Zürich and researcher, extensive experience with various pharma companies on microbial physiology, cholesterol metabolism, co-author of 7 patents.
XAVIER MANIÈRE
XAVIER MANIÈRE Head of R&D
Co-founder of Meletios, Pharmacist, PhD specialized in microbiology, former director of discovery biology at Stellate therapeutics.
CATHERINE GUITTET
CATHERINE GUITTETDirector of Clinical Development
Pharmacist with more than 20 years of experience in clinical development in the Pharma and Biotech industry, in Europe and in the USA.
ANNA ELGART
ANNA ELGART Project Manager
Polytechnique & Mines ParisTech Engineer, experience with various healthcare players: hospitals, medical device, research laboratories.
RODRICK MONTJEAN
RODRICK MONTJEANDiscovery Project Manager
Ph.D (Paris Descartes University), specialized in Biochemistry, Molecular and Cellular Biology, experience in both preclinical development and elucidation of drug mechanisms of action.
LYDIE BOUSSICAULT
LYDIE BOUSSICAULTDiscovery Project Manager
Ph.D (Pierre and Marie Curie University), specialized in Biochemistry and Cellular Biology, experience in biotech (preclinical project management).
STEFANO BERNA
STEFANO BERNACMC Manager
Biotechnologist, specialized in Biomolecular Sciences. CMC specialist with experience in Drug Development on multiple pharmaceutical forms, CDMO/CMO management and Module 3.

Our Board

Patrice Garnier
Patrice Garnier
President and co-founder of Meletios Therapeutics. Originator of 6 start-ups. PhD in quantum physics / nanotechonogy.
Alexandre Mouradian
Alexandre Mouradian
Chairman and Founder of Eurekare, a biotech fund. Chairman of the Spinoza Foundation, a charitable organization set up to promote a deeper understanding of the challenges which our global society faces.
Catherine Martre
Catherine Martre
CEO of Meletios Therapeutics. Leading strategic positions in the pharma industry, commercial operation and market access in Advicenne, a French Biotech company.
Emmanuel de Rivoire
Emmanuel de Rivoire
General Manager of Kinnov Therapeutics, a French Biotech dedicated to addiction. Senior international executive in Pharma industry (Takeda, Nycomed, Roche, GSK, Abbott), he has 30+ years experience in Europe, Middle East/Africa and Asia.
Franck Mouthon
Franck Mouthon
CEO and founder of Theranexus, a French biotech dedicated to rare diseases in Neurology. Franck is also President of the French Biotech companies association.
Gerard Le Fur
Gerard Le Fur
Former CEO of Sanofi-Aventis, and renown pharmacologist. Head of Sanofi’s Research and Development for several years. Member of the French Science Academy.
Stephane Delacote
Stephane Delacote
Founder of Tigres Investissement. He worked in investment banks and is skilled in nonprofit organizations and entrepreneurship. Stephane is an experienced business development professional graduated from Ecole des Mines de Paris.

OUR SCIENTIFIC ADVISORS

Felix Rey
Felix Rey
Pr. Felix Rey is leading the Structural Virology Unit at Institut at the Institut Pasteur. His research focus has included the 3D structures of viral polymerases and the study of viral envelope proteins. Felix is a member of the French Sciences Academy.
Marco Vignuzzi
Marco Vignuzzi
Marco Vignuzzi holds a PhD in microbiology and virology. He founded his laboratory at Institut Pasteur Paris in 2008 and joined A*Star-IDLab in Singapore in 2022. He is an expert in virus evolutionary mechanisms and Defective Viral Genomes.
Antoine Danchin
Antoine Danchin
Mathematician and molecular biologist, Pr. Antoine Danchin is a pioneer in synthetic biology. He was the director of the Department Genomes and Genetics at the Institut Pasteur in Paris and is also a member of the French Sciences Academy.
Vincent Maréchal
Vincent Maréchal
Vincent Maréchal is a professor of Virology of Sorbonne Université, INSERM unit director at Saint-Antoine Hospital/APHP. He is also the founder of Obepine network for the epidemiological surveillance of SARS-Cov-2 in wastewater.

meletios’ R&D STRATEGY

Meletios develops two complementary programs to prevent the virus from taking advantage of the host resources.

One of our programs consists in developing host targeting molecules (HTA) targeting metabolic resources hijacked by viruses. Our most advanced drug candidate has a robust in vitro and in vivo proof of concept on the coronavirus family and influenza H1N1. This molecule is now developed in order to fulfill the regulatory requirements and enter into clinical phase II before end of 2023.

Another program of Meletios is based on a disruptive technology platform originating from the Institut Pasteur. It relies on Defective Viral Genomes (DVG) that directly interfere with the protein expression machinery hijacked by viruses. Two candidates are developed against Zika and Chikungunya.

HOST TARGETING AGENTS

Target:
Metabolic resources hijacked by viruses

What:
Small molecules

Strength:
Biomarkers predictive of viral diseases

DEFECTIVE VIRAL GENOMES

Target:
Protein expression machinery hijacked by viruses

What:
RNA sequences

Strength:
– Disruptive technology platform
– Originating from a prestigious academic center: Institut Pasteur

MELETIOS PIPELINE

Meletios Pipeline

NEWS

2 November 2022 – Meletios Therapeutics receives €5.2 million in funding from the European Innovation Council Accelerator for the clinical development of its candidate MLT103
Read our Press Release
2 March 2022 – License agreement with the Institut Pasteur for a new class of antivirals: Interview – Marco Vignuzzi (Institut Pasteur) x Catherine Martre (Meletios Therapeutics)
Watch the interview
Read our Press Release
7 September 2021 – 3 questions to Catherine Martre, CEO of Meletios Therapeutics
Watch the interview
Read our Press Release

Careers

You are interested in joining our team? Do not hesitate to submit your application with a cover letter and resume at contact@meletiostx.com!

Please send your application to contact@meletiostx.com

Get in touch with us

You are interested in a partnership opportunity, a job or just want to know more about us? We’d like to hear from you. Don’t hesitate to reach us directly!

 

Follow us on LinkedIn…
and on Twitter!